2018
DOI: 10.1007/s40264-018-0742-3
| |Summarize |Cite
|
Sign up to set email alerts

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development

Abstract: IntroductionRecombinant human luteinizing hormone (r-hLH) is used in a fixed-ratio combination with recombinant human follicle-stimulating hormone (r-hFSH) for the stimulation of follicular development.ObjectiveThe objective of this article was to conduct a review of safety data to evaluate the risks of r-hFSH/r-hLH treatment.MethodsData were retrieved from the Global Safety Database (Merck KGaA, Darmstadt, Germany) including reports from healthcare professionals, patients, health authorities, clinical trials,… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
2
1
0

Citation Types

1
3
0
0

Year Published

Range
2018
2018
2026
2026

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

Cited by 7 publications

(4 citation statements)

References 25 publications

1
3
0
0
Order By: Relevance
How the paper below cites the one you are viewing
“…Mild OHSS was reported in four patients who received an embryo transfer, all of which resolved. There were no deaths reported in this study, and the safety results are consistent with the known safety profile of the r-hFSH:r-hLH 2:1 combination [4,38]. Therefore, the higher pregnancy rates observed in the current study were not accompanied by an increased risk of OHSS, and the incidence of OHSS was similar to that observed in the ESPART trial (<1% of patients in both studies) [6].…”
Section: Discussion
supporting
confidence: 88%